Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
1.
Pharmacogenomics J ; 16(3): 231-7, 2016 06.
Artículo en Inglés | MEDLINE | ID: mdl-26169577

RESUMEN

The most common side effect of angiotensin-converting enzyme inhibitor (ACEi) drugs is cough. We conducted a genome-wide association study (GWAS) of ACEi-induced cough among 7080 subjects of diverse ancestries in the Electronic Medical Records and Genomics (eMERGE) network. Cases were subjects diagnosed with ACEi-induced cough. Controls were subjects with at least 6 months of ACEi use and no cough. A GWAS (1595 cases and 5485 controls) identified associations on chromosome 4 in an intron of KCNIP4. The strongest association was at rs145489027 (minor allele frequency=0.33, odds ratio (OR)=1.3 (95% confidence interval (CI): 1.2-1.4), P=1.0 × 10(-8)). Replication for six single-nucleotide polymorphisms (SNPs) in KCNIP4 was tested in a second eMERGE population (n=926) and in the Genetics of Diabetes Audit and Research in Tayside, Scotland (GoDARTS) cohort (n=4309). Replication was observed at rs7675300 (OR=1.32 (1.01-1.70), P=0.04) in eMERGE and at rs16870989 and rs1495509 (OR=1.15 (1.01-1.30), P=0.03 for both) in GoDARTS. The combined association at rs1495509 was significant (OR=1.23 (1.15-1.32), P=1.9 × 10(-9)). These results indicate that SNPs in KCNIP4 may modulate ACEi-induced cough risk.


Asunto(s)
Inhibidores de la Enzima Convertidora de Angiotensina/efectos adversos , Tos/inducido químicamente , Tos/genética , Proteínas de Interacción con los Canales Kv/genética , Polimorfismo de Nucleótido Simple , Estudios de Casos y Controles , Biología Computacional , Tos/etnología , Bases de Datos Genéticas , Registros Electrónicos de Salud , Femenino , Frecuencia de los Genes , Predisposición Genética a la Enfermedad , Estudio de Asociación del Genoma Completo , Humanos , Modelos Logísticos , Masculino , Análisis Multivariante , Oportunidad Relativa , Fenotipo , Medición de Riesgo , Factores de Riesgo , Escocia , Estados Unidos
2.
Pharmacogenomics J ; 15(3): 272-7, 2015 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-25266681

RESUMEN

Several reports have shown that statin treatment benefits patients with asthma; however, inconsistent effects have been observed. The mir-152 family (148a, 148b and 152) has been implicated in asthma. These microRNAs suppress HLA-G expression, and rs1063320, a common SNP in the HLA-G 3'UTR that is associated with asthma risk, modulates miRNA binding. We report that statins upregulate mir-148b and 152, and affect HLA-G expression in an rs1063320-dependent fashion. In addition, we found that individuals who carried the G minor allele of rs1063320 had reduced asthma-related exacerbations (emergency department visits, hospitalizations or oral steroid use) compared with non-carriers (P=0.03) in statin users ascertained in the Personalized Medicine Research Project at the Marshfield Clinic (n=421). These findings support the hypothesis that rs1063320 modifies the effect of statin benefit in asthma, and thus may contribute to variation in statin efficacy for the management of this disease.


Asunto(s)
Asma/tratamiento farmacológico , Asma/genética , Antígenos HLA-G/genética , Inhibidores de Hidroximetilglutaril-CoA Reductasas/uso terapéutico , Polimorfismo de Nucleótido Simple/genética , Regiones no Traducidas 3'/genética , Alelos , Línea Celular Tumoral , Femenino , Células Hep G2 , Humanos , Masculino , MicroARNs/genética , Persona de Mediana Edad , Riesgo
3.
Osteoporos Int ; 22(4): 1069-77, 2011 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-20533026

RESUMEN

UNLABELLED: This very large dual X-ray absorptiometry (DXA) cohort confirmed a significant, inverse relationship between bone mineral density (BMD) Z-scores and the presence of secondary causes of osteoporosis but receiver operating characteristic (ROC) curves indicate that Z-score diagnostic thresholds (such as -2.0) discriminate poorly between the presence and absence of secondary causes of osteoporosis. INTRODUCTION: BMD Z-score diagnostic thresholds have been proposed to detect secondary causes of osteoporosis. To determine the sensitivity and diagnostic utility of such thresholds, we analyzed comprehensive BMD and personal health information data from a large, multispecialty group practice. METHODS: Adult subjects were assigned their lowest axial BMD Z-score and ICD-9 diagnosis codes for secondary causes of osteoporosis when cited at least twice in their electronic medical record. Multiple logistic regression was used to model the prevalence of matching ICD-9 codes as a function of Z-score. ROC curves were used to investigate various Z-score cut points for sensitivity and specificity. RESULTS: Eighteen thousand six hundred seventy-four subjects were analyzed. Secondary causes of osteoporosis were identified in 31% of men and 16% of women. The frequency of secondary causes varied with age and between genders and varied inversely with Z-score. No inflection point was observed in this relationship to suggest a useful clinical decision threshold. The difference in mean Z-score of those with and without a secondary cause of osteoporosis was biologically slight (±0.3). Low Z-score diagnostic thresholds were insensitive to the presence of secondary causes of osteoporosis and provided relatively poor predictive value. CONCLUSIONS: This DXA cohort confirmed a significant inverse relationship between Z-score and the presence of secondary causes of osteoporosis but diagnostic Z-score thresholds discriminate poorly between the presence and absence of secondary causes of osteoporosis. If only patients with very low Z-scores are evaluated for secondary causes of osteoporosis the diagnostic specificity may be high but most cases will be missed.


Asunto(s)
Densidad Ósea/fisiología , Osteoporosis/etiología , Absorciometría de Fotón/métodos , Adolescente , Adulto , Distribución por Edad , Anciano , Anciano de 80 o más Años , Métodos Epidemiológicos , Femenino , Humanos , Clasificación Internacional de Enfermedades , Masculino , Persona de Mediana Edad , Osteoporosis/fisiopatología , Adulto Joven
4.
Clin Pharmacol Ther ; 103(2): 310-317, 2018 02.
Artículo en Inglés | MEDLINE | ID: mdl-27981563

RESUMEN

Authorized generics are identical in formulation to brand drugs, manufactured by the brand company but marketed as a generic. Generics, marketed by generic manufacturers, are required to demonstrate pharmaceutical and bioequivalence to the brand drug, but repetition of clinical trials is not required. This retrospective cohort study compared outcomes for generics and authorized generics, which serves as a generic vs. brand proxy that minimizes bias against generics. For the seven drugs studied between 1999 and 2014, 5,234 unique patients were on brand drugs prior to generic entry and 4,900 (93.6%) switched to a generic. During the 12 months following the brand-to-generic switch, patients using generics vs. authorized generics were similar in terms of outpatient visits, urgent care visits, hospitalizations, and medication discontinuation. The likelihood of emergency department (ED) visits was slightly higher for authorized generics compared with generics. These data suggest that generics were clinically no worse than their proxy brand comparators.


Asunto(s)
Sustitución de Medicamentos , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos/etiología , Medicamentos Genéricos/uso terapéutico , Reclamos Administrativos en el Cuidado de la Salud , Adulto , Anciano , Atención Ambulatoria , Minería de Datos/métodos , Sustitución de Medicamentos/efectos adversos , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos/diagnóstico , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos/terapia , Medicamentos Genéricos/efectos adversos , Registros Electrónicos de Salud , Servicio de Urgencia en Hospital , Medicina Basada en la Evidencia/métodos , Femenino , Hospitalización , Humanos , Masculino , Persona de Mediana Edad , Seguridad del Paciente , Vigilancia de Productos Comercializados , Estudios Retrospectivos , Medición de Riesgo , Factores de Riesgo , Factores de Tiempo
5.
Inj Prev ; 12(1): 46-51, 2006 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-16502564

RESUMEN

OBJECTIVE: Evaluate the effectiveness of a United States state law, Wisconsin Act 455, in reducing highway tractor crashes involving youth operators. DESIGN: Policy outcome evaluation involving review of a retrospective case series. SETTING: Youth highway tractor crashes from Wisconsin for the years 1994-2003 that resulted in a fatality, injury, and/or property damage. SUBJECTS: One hundred and forty six tractor crash cases involving operators younger than 16 years. METHODS: Describe and model the tractor crash patterns before and after enactment of the law, and examine the relation between the contributing circumstances identified in the crash reports and the content covered in the mandated tractor certification course. RESULTS: There was neither a significant change in the number of youth tractor crashes after the law was passed, nor any reduction in the proportion of crashes where the youth operator was designated at fault. The tractor certification course did not cover the major factors contributing to youth tractor crashes on public roads. CONCLUSIONS: No significant effect of the law was detected and crash rates at the end of the study period were similar to those before Wisconsin Act 455. The authors'findings should not be construed to suggest that public policy, in general, is an ineffective strategy for the prevention of pediatric agricultural injuries. Negotiating a balance in public policy debates will be a challenge, but it is clear that future policy initiatives need to identify and implement the right policy for the right problem.


Asunto(s)
Accidentes de Trabajo/prevención & control , Accidentes de Tránsito/prevención & control , Agricultura/instrumentación , Vehículos a Motor/legislación & jurisprudencia , Prevención de Accidentes/legislación & jurisprudencia , Prevención de Accidentes/normas , Accidentes de Trabajo/legislación & jurisprudencia , Accidentes de Tránsito/legislación & jurisprudencia , Accidentes de Tránsito/estadística & datos numéricos , Adolescente , Niño , Política de Salud/legislación & jurisprudencia , Humanos , Evaluación de Programas y Proyectos de Salud , Política Pública , Estudios Retrospectivos , Wisconsin
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA